NASDAQ:JNCE - Jounce Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.25
  • Forecasted Upside: 81.30 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.86
▼ -0.19 (-2.36%)

This chart shows the closing price for JNCE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Jounce Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JNCE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JNCE

Analyst Price Target is $14.25
▲ +81.30% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Jounce Therapeutics in the last 3 months. The average price target is $14.25, with a high forecast of $17.00 and a low forecast of $10.00. The average price target represents a 81.30% upside from the last price of $7.86.

This chart shows the closing price for JNCE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Jounce Therapeutics. This rating has held steady since January 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$10.00High
8/5/2021Piper SandlerLower Price TargetOverweight$20.00 ➝ $17.00Low
3/15/2021Piper SandlerInitiated CoverageOverweight$20.00High
2/28/2021Robert W. BairdReiterated RatingBuyLow
2/26/2021HC WainwrightBoost Price TargetBuy$11.00 ➝ $15.00High
12/4/2020HC WainwrightReiterated RatingBuy$11.00High
11/10/2020Roth CapitalLower Price TargetBuy$28.00 ➝ $15.00High
11/2/2020Raymond JamesDowngradeStrong-Buy ➝ Market PerformHigh
9/18/2020Roth CapitalInitiated CoverageBuy$28.00Low
9/2/2020Raymond JamesReiterated RatingBuy$12.00Low
9/2/2020HC WainwrightBoost Price TargetBuy$8.00 ➝ $9.00Low
8/21/2020JPMorgan Chase & Co.Reiterated RatingSellLow
8/10/2020HC WainwrightReiterated RatingBuy$8.00High
5/7/2020HC WainwrightLower Price TargetBuy$10.00 ➝ $8.00High
3/25/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy$11.00High
3/2/2020HC WainwrightLower Price TargetBuy$13.00 ➝ $10.00High
2/27/2020CowenReiterated RatingHoldLow
2/7/2020CowenReiterated RatingHoldHigh
11/12/2019CowenReiterated RatingHoldHigh
8/11/2019JPMorgan Chase & Co.Reiterated RatingSellMedium
3/7/2019JPMorgan Chase & Co.Reiterated RatingSellHigh
11/14/2018HC WainwrightSet Price TargetBuy$13.00Medium
11/13/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
11/13/2018CowenReiterated RatingHoldHigh
10/23/2018Raymond JamesLower Price TargetOutperform ➝ Outperform$13.00 ➝ $12.00High
8/13/2018HC WainwrightSet Price TargetBuy$13.00Medium
8/10/2018JPMorgan Chase & Co.Lower Price TargetNeutral ➝ Hold$12.00 ➝ $10.00High
8/9/2018CowenReiterated RatingHoldHigh
6/28/2018Raymond JamesInitiated CoverageOutperform$13.00Medium
6/5/2018CowenDowngradeOutperform ➝ Market PerformHigh
6/4/2018Robert W. BairdLower Price TargetOutperform ➝ Buy$35.00 ➝ $20.00High
6/4/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$12.00High
5/31/2018Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$10.00Low
5/17/2018HC WainwrightSet Price TargetBuy$19.00High
5/17/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$37.00 ➝ $13.00High
5/10/2018HC WainwrightSet Price TargetBuy$33.00High
4/27/2018HC WainwrightInitiated CoverageBuy ➝ Buy$33.00High
3/8/2018Robert W. BairdSet Price TargetBuy$35.00High
11/13/2017JPMorgan Chase & Co.Set Price TargetBuy$28.00N/A
11/10/2017Robert W. BairdReiterated RatingBuy$30.00N/A
9/18/2017Robert W. BairdReiterated RatingOutperform$30.00Low
9/12/2017Robert W. BairdReiterated RatingBuy$30.00Medium
6/9/2017CowenReiterated RatingBuyLow
4/20/2017CowenReiterated RatingBuyMedium
2/21/2017CowenInitiated CoverageOutperformN/A
2/21/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$28.00N/A
2/21/2017Robert W. BairdInitiated CoverageOutperform ➝ Outperform$30.00N/A
2/21/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ OutperformN/A
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/30/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Jounce Therapeutics logo
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $7.86
Low: $7.71
High: $8.10

50 Day Range

MA: $6.17
Low: $5.04
High: $8.73

52 Week Range

Now: $7.86
Low: $5.03
High: $14.84

Volume

18,998 shs

Average Volume

478,912 shs

Market Capitalization

$402.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Jounce Therapeutics?

The following Wall Street analysts have issued reports on Jounce Therapeutics in the last twelve months: HC Wainwright, Piper Sandler, Raymond James, Robert W. Baird, Roth Capital, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for JNCE.

What is the current price target for Jounce Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Jounce Therapeutics in the last year. Their average twelve-month price target is $14.25, suggesting a possible upside of 81.3%. Piper Sandler has the highest price target set, predicting JNCE will reach $17.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $10.00 for Jounce Therapeutics in the next year.
View the latest price targets for JNCE.

What is the current consensus analyst rating for Jounce Therapeutics?

Jounce Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe JNCE will outperform the market and that investors should add to their positions of Jounce Therapeutics.
View the latest ratings for JNCE.

What other companies compete with Jounce Therapeutics?

How do I contact Jounce Therapeutics' investor relations team?

Jounce Therapeutics' physical mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company's listed phone number is (857) 259-3840 and its investor relations email address is [email protected] The official website for Jounce Therapeutics is www.jouncetx.com.